Pentwater Capital Management LP Atreca, Inc. Transaction History

Pentwater Capital Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 14, 2019	SELL	$10.42 - $22.04 $260,500 - $551,000	-25,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $426,750 - $471,000	25,000 New	25,000 $471,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Pentwater Capital Management LP with notifications on news.